Two different oral ofloxacin regimens, a daily single-dose regimen with 200 mg (Regimen I) and an every-two-week multidose regimen with 3 x 200 mg/day (Regimen II) was compared as to the efficacy in controlling repeated acute exacerbations of chronic respiratory tract infections. Fifty-eight patients consisting of 19 patients each of bronchiectasis and pulmonary emphysema, 10 patients of chronic bronchitis, 5 patients of old pulmonary tuberculosis, 4 patients of diffuse panbronchiolitis and 1 patient of multiple pulmonary bullae were evaluated: 32 patients in Regimen I and 26 patients in Regimen II. The corrected mean incidence of exacerbations per case decreased from pre-study 2.47 to intra-study 0.59 in Regimen I, and from pre-study 2.66 to intra-study 0.95 in Regimen II, respectively, with a statistically significant difference (p <0.05, respectively). Only one of 12 persistent isolates of Pseudomonas aeruginosa acquired a certain degree of resistance to ofloxacin. Adverse reactions were found in six of 66 patients. We conclude that long-term administration of an new-quinolone, especially a daily single-dose regimen with ofloxacin, is useful to control acute exacerbations of chronic repiratory tract infections.
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ofloxacin Grassi et al. 1987) . The objective of the present study was to compare the efficacy of two different oral ofloxacin regimens for the control of acute exacerbations of chronic RTI. In our study, ofloxacin was used, not for the treatment, but for the prophylaxis and control of acute exacerbations of chronic RTI. Part of this study has been reported (Watanabe 1991; Watanabe and Motomiya 1991) . Thereafter the number of patients was increased to arrive at a more definite conclusion.
SUBJECTS AND METHODS
A total of 11 institutions participated in this study. Seventy-four patients with chronic RTI's, who had one or more episodes of acute exacerbation during the last six months prior to the study, were included in this study. According to the study protocol, 5 patients each were assigned at random to one of the following two different ofloxacin regimens in each institution.
Regimen I was a daily single-dose of 200 mg of ofloxacin, given every morning for six months. Regimen II was a multi-dose regimen in which 600 mg of ofloxacin was administered: 3 x 200 mg a day for alternate two weeks (six repaeted courses of two medication weeks plus two non-medication weeks). The regimens were started at an episodefree stable time point and was continued for six months. Dropout patients within one month after the start of administration were excluded from evaluation. When exacerbation occurred in Regimen I, the daily dose of ofloxacin was increased from 200 mg to 600 mg (3 x 200 mg) at the discretion of an attending physician., Ofloxacin was given for the control of acute exacerbation during the non-medication period of Regimen II. When symptoms due to acute exacerbations had improved, the regimen before exacerbation was resumed. After six months, the efficacy of the two regimens was compared with reference to the following points: a) incidence of acute exacerbation, b) control of acute exacerbation, c) incidence of the emergence of resistant strains, d) safety and usefulness of regimens.
RESULTS

Subjects for study
Of a total of 74 patients (38 in Regimen I and 36 in Regimen II) enrolled in the study, 8 patients (2 and 6, respectively) dropped out because they came to the hospital only once, or ofloxacin was withdrawn within one month after the start of the study. Of the remaining 66 patients (36 and 30, respectively), 8 patients were excluded from clinical evaluation because they had had no exacerbations during the pre-study six months. Thus 58 patients (32 and 26 , respectively) were included in the clinical evaluation. One patient was treated for only one day due to side effects. The remaining 57 patients were treated for more than one month .
Patient characteristics in the two regimens as regards sex, age and body weight are shown in Table 1 . The body weight of patients in this study was within the normal range of the Japanese. As shown in Table 2 , of the 19 cases of bronchiectasis, 7 were in Regimen I and 12 in Regimen II. The number of patients with bronchiectasis in Regimen II and that of pulmonary emphysema in Regimen I slightly exceeded those of the counterparts.
However there was no statistically significant difference between the two regimens as regards diagnostic classification. There was no statistically significant difference either between the two regimens as regards severity of the disease based on the evaluation by an attending physician.
Pseudomonas aeruginosa was a persistent isolate in 12 patients consisting of 6 patients with bronchiectasis, 3 patients each with DPB Effects on acute exacerbations Incidence of acute intra-study exacerbations is shown in Table 3 . Of the 32 patients in Regimen I, 22 patients experienced no intra-study exacerbations. The remaining 10 patients in Regimen I had 16 episodes of acute exacerbation, but only one of them required hospitalization. In Regimen II, 13 of the 26 patients had no exacerbations. The remaining 13 patients experienced 20 episodes of Incidence of acute intra-study exacerbation Organisms isolated, medications and efficacy of therapy at each exacerbation in regimens I and II acute exacerbation, and seven of them required hospitalization. The incidence of exacerbation was corrected per case on the assumption that six-month treatment was completed in each patient, because some patients received treatment for less than six months and some discontinued treatment by themselves. As shown in Table 4 , the corrected mean incidence of exacerbation per case during six-month decreased from pre-study 2.47 to intra-study 0.59 in Regimen I, and from prestudy 2.66 to intra-study 0.95 in Regimen II with a statistically significant difference (p <0.05), respectively.
Organisms causing acute exacerbations with reference to therapeutic effects during study
In 36 episodes of exacerbation, twenty strains of bacteria were documented as shown in Table 5 : seven strains of Pseudomonas aeruginosa, four strains each of Staphylococcus aureus and Haemophilus inf luenzae, two strains each of Streptococcus pneumoniae and Moraxella catarrhalis, and one strain of Serratia marcescens. There was no statistically significant difference in the species of microbial isolates between two regimens. Causative bacteria were found in seven of the 16 episodes of exacerbation (43.8%) and in 15 of 21 (71.4%) in Regimen I and Regimen II, respectively. Table 6 shows the microbial isolates, treatment given and the efficacy of regimens at each intra-study exacerbation.
A half of the episodes of exacerbation in Regimen I could be controlled merely by increasing the dosage of ofloxacin to 600 mg in outpatient clinic. In contrast, about a half of the patients who had acute exacerbation in Regimen II needed an additional administration of antimicrobial agents for parenteral use after hospitalization, and the other half needed ofloxacin during the non-medication period. As a whole, the efficacy of oral ofloxacin at acute exacerbations was remarkable.
Adverse reactions and emergence of resistant strain Table 7 shows intra-study adverse reactions. dizziness, sleep disturbance, anorexia, numbness in both legs, and elevated GOT, GPT values were observed in a total of 6 patients, i.e. in 2 patients of Regimen I and in 4 patients of Regimen II, respectively. The adverse reactions disappeared upon withdrawal of ofloxacin, or upon reduction of its dosage from 600 mg/day to 400 mg/day in three cases each, respectively. Six strains each of P. aeruginosa were persistent intrastudy isolates in both Regimens. Only one strain from a patient in Regimen I in whom no acute intra-study exacerbation was observed acquired a certain degree ("susceptible" to "intermediate") of resistance to ofloxacin tested in a disk sensitivity test.
DISCUSSION
It is important for the improvement of prognosis of patients with chronic RTI's to control an occurrence of exacerbation in outpatient clinic. Also it is cost-effective to control an occurrence of exacerbation because the number of times of admission and parenteral therapy can be decreased (Sato et al. 1991) . In recent years, new-quinolones have been reported to be effective in the treatment of acute exacerbations of chronic RTI's (Maesen et al. 1985 (Maesen et al. ,1986 ; Hoogkamp-Korstanje and Klein 1986; Davies and Maesen 1987; Grassi et al. 1987) . Oral ofloxacin in this study was used not for the treatment, but for the control or prophylaxis of acute exacerbations of chronic RTI's. In the present study, two oral ofloxacin regimens were compared to evaluate the efficacy of quinolone in controlling acute exacerbations of chronic RTI's. Hayashi and Onuma (1989) have already reported the efficacy and usefulness of an every-two-week multi-dose regimen of newquinolone, which is essentially the same as Regimen II of the present study, in controlling acute exacerbations of chronic RTI's. Their regimen was rather complex and was difficult for patients to follow.
In the present study, a daily single-dose regimen of ofloxacin (Regimen I) was compared with Regimen II. Patients who had only one or two episodes of acute exacerbation were also included in the present study. However both regimens could be evaluated as excellent as regards usefulness, because the incidence of acute exacerbations was significantly reduced in both regimens. It is to be noted, in particular, that the efficacy of ofloxacin in Regimen I exceeded that in Regimen II. The corrected mean incidence of exacerbations per case over six months was reduced from pre-study 2.47 to intra-study 0.59 in Regimen I, and from pre-study 2.66 to intra-study 0.95 in Regimen II, respectively. In Regimen II, acute exacerbations were observed frequently during the non-medication period, and a parenteral administration of antimicrobials after hospitalization was required frequently for the control of exacerbation. In contrast, almost a half of exacerbations in Regimen I could be controlled merely by increasing the dosage of ofloxacin. In this study, a total dosage of ofloxacin administered to one patient in Regimen I was two-thirds of that in regimen II. To summarize, patients who have repeated episodes of exacerbation should be treated with either Regimen I, or Regimen II, preferably with Regimen I.
The emergence of resistant strains was not a major problem, because only one of the 12 persistent intra-study isolates of P. aeruginosa acquired a certain degree of resistance to ofloxacin. No acute intra-study exacerbation was observed in the patient from whose sputum the above ofloxacin-resistant strain of P. aeruginosa was isolated, and the outcome of treatment for this patient was evaluated as "excellent" .
No severe intra-study adverse reactions were observed. The incidence of adverse reactions in Regimen I (2/36) was lower than that in Regimen II (4/30). High incidence of adverse reactions in Regimen II may be ascribed to repeated administration of high-dose ofloxacin. Therefore, Regimen I with a low dose ofloxacin was considered to be safer and more useful than Regimen II for the long-term treatment as regards adverse reactions.
We therefore conclude that the long-term administration of ofloxacin, in particular, the daily single-dose regimen is useful for the control of acute exacerbations of chronic RTI's. Moreover it was found that the daily single-dose prophylaxis was more effective than the multi-dose regimen of 600 mg in decreasing the incidence of adverse reactions and of resistant strains, and was more cost-effective in the treatment of chronic RTI's (Bantz et al. 1987; MacCabe et al 1989) . The results of the present study indicate that long-term prevention with ofloxacin is a possible alternative in managing patients with acute exacerbations of chronic RTI's.
